The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients ...

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...

Evox Therapeutics Ltd ("Evox" or the "Company"), a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing mo ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

The More the Merrier, a new original Hallmark movie, features Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during ...